ACROBiosystems: Detailed Company Information & Corporate Profile
Summary
ACROBiosystems, headquartered in Newark, Delaware, was founded in 2010 and operates as an independent biotech company with a workforce of 500‑1000 employees. The organization specializes in a proprietary HEK293 expression platform complemented by an in‑house developed enzymatic and chemical biotin labeling technique.
Their portfolio includes COVID‑19 antigens and antibodies, SARS-CoV-2 related kit products, reagents for vaccine development and evaluation, as well as targets for CAR‑T cell therapy, antibody‑drug conjugates, bispecific antibodies (CD3, Fc receptors), and multi‑pass transmembrane proteins. The company also offers GMP‑grade cytokines, anti‑idiotypic antibodies, enzymes, MABSOL biotinylated proteins, and services for cell gene therapy.
ACROBiosystems reports annual revenue between $50 million and $100 million. Key leadership roles include Xiamin Chen as Vice President of Commercial Operations, Rosanna Zhang overseeing Strategy and Corporate Development, YU SUN directing Product Development and Discovery, and Huang Xu leading Sales and Marketing.
| ACROBiosystems Website | acrobiosystems.com |
| Social Links |    |
| Phone Number | +1 800-810-0816 |
| Industries | |
| ACROBiosystems Headquarters Address | 1 Innovation Way, Newark, Delaware, 19711 US |
| Company Size | 500-1000 employees |
| Specialities & Services | Proprietary HEK293 expression platform, In-house developed enzymatic and chemical biotin labeling technique, covid-19 antigens and antibodies, CAR-T, Reagents for COVID-19 vaccine development and evaluation, SARS-CoV-2 Related Kit Products, Targets for Antibody-Drug Conjugates, Hot target for bispecific antibody, CD3, Bispecific Antibody, Sars-cov-2 mutants, ADCs, Sars-cov-2 kits, Targets for CAR-T Cell Therapy, Multi-pass Transmembrane Proteins and Technology Platforms, Immune Checkpoint, Cytokine, BsAb targets, Fc Receptors, MABSOL Biotinylated Protein, Enzymes, Anti-idiotypic Antibodies, Cell Gene Therapy, GMP grade Cytokines |
| Technologies | Flask, ASP.NET |
| DMA Code | Delaware Valley |
| Founded | 2010 |
| Estimated Annual Revenue | $50M - 100M |
| Operating Status | Independent Company |
| Updated: | 2026-09-19 |
Competitors
Name | Founded | Type | Employees |
|---|---|---|---|
| 2014 | Sole Proprietorship | 1 - 25 | |
| - | - | 1-10 | |
| 2008 | - | 10-50 |
Estimated Website Traffic
The chart shows a growth in traffic to the acrobiosystems.com website. In September, traffic increased to 19803, compared to 16771 in the previous month. The highest traffic in 2026 was recorded in March, reaching 23413 visits.
Workforce Turnover
Number of employees switched from or switched to
Departmental sample breakdown
Length of Employment
ACROBiosystems's workforce includes employees across a wide range of tenure levels.
8% have been with the company for less than 1 year25% have been with the company for 1 to 2 years17% have been with the company for 3 to 4 years17% have been with the company for 5 to 7 years25% have been with the company for 8 to 10 years8% have been with the company for more than 11 years
Companies Similar to ACROBiosystems
ACROBiosystems Corporate Information: FAQ
Data Privacy
GDPR COMPLIANT
SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.
CCPA COMPLIANT
SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.
